Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE:NVS) Sandoz, Bloomberg reports, citing people close to the matter

  • The publication said that the private equity firms are discussing a potential joint offer for the Novartis unit. 
  • Separately, Advent International, Hellman & Friedman, and KKR & Co. are sizing up their approaches, Bloomberg's sources said.
  • Sandoz is a sizable target, and some private equity funds could partner to bid. 
  • Swedish firm EQT AB has been working with the Struengmann family, who previously sold their generic pharmaceutical business to Novartis, as it studies an offer for Sandoz.
  • But it's early yet, and the suitors may decide against teaming up or proceeding with bids altogether, Bloomberg said.
  • Related: Novartis May Have Buyer(s) For Its Sandoz Unit - Report.
  • The interest in Sandoz comes as Novartis takes a magnifying lens to the business. Novartis launched a strategic review of its generics arm in October. The Company said it would provide an update by the end of 2022.
  • Price Action: NVS shares are up 1.16% at $87.92 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.